The Phase 3 trial (NCT06214741) for Survodutide (BI 456906) in Chinese adults with overweight or obesity is scheduled for primary completion on 2025-07-29. This study investigates whether Survodutide helps participants achieve weight loss.
Background
Survodutide (BI 456906) is an investigational drug being evaluated for its potential in weight management. This particular study focuses on its efficacy in Chinese adults living with overweight or obesity.
Trial design
The study (NCT06214741) is a Phase 3 trial designed to assess the effectiveness of Survodutide in Chinese adults aged 18 years or older who are living with overweight or obesity. Participants were eligible if they had a body mass index (BMI) of 28 kg/m^2 or higher, or 24 kg/m^2 or higher with at least one weight-related problem. The trial enrolled 307 participants, who were randomly assigned to one of three groups: two receiving different doses of Survodutide, and one receiving a placebo.
What this means
The primary completion of this Phase 3 trial signifies a major milestone in the development of Survodutide for weight management in the Chinese population. Once the data from this study are analyzed and released, they will provide crucial insights into the potential of Survodutide as a therapeutic option for individuals with overweight or obesity in China. The findings are anticipated to inform future regulatory decisions and clinical practice regarding the use of this investigational drug.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06214741, titled "A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight," was recorded with a primary completion date of 2025-07-29 on clinicaltrials.gov.